Kindred Biosciences Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices rise 2% as US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Kindred Biosciences (KIN) PT Raised to $16 at H.C. Wainwright
August 13, 2018 12:14 PM EDTH.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Kindred Biosciences (NASDAQ: KIN) to $16.00 (from $12.00) while maintaining a Buy rating.
Ramakanth said initial signs show a good appetite for Mirataz.
... MoreKindred Biosciences (KIN) Reports In-Line Q2 EPS
August 9, 2018 4:36 PM EDTKindred Biosciences (NASDAQ: KIN) reported Q2 EPS of ($0.39), in-line with the analyst estimate of ($0.39).
As of June 30, 2018, KindredBio had $109.9 million in cash, cash equivalents and investments, compared with $82.5 million as of December 31, 2017. Net cash used in operating activities for the first six months of 2018 was... More
